Abbott Labs has continued to lag competitors like Boston Scientific and Stryker that are seen as more innovative and more likely to generate attractive revenue growth and margins. I think Abbott could ...
Abbott Laboratories (ABT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and ...
Abbott had a visible slowdown in top line and earnings margin starting in 2022 and continued in Q1's data. It is likely to have more persistent weakness in the bottom line in '23 and '24 to show up.
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Organic sales growth for the underlying ...
Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4 ...
Revenues from the company's medical devices segment grew 12% in the quarter, fueled by double-digit gains in diabetes care, heart failure, electrophysiology, and rhythm management, with continuous ...
Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments. The healthcare products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback